Report Store Get Proposal

Home Blog Notizia 37

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Pfizer/BioNTech COVID-19 Vaccine; Biogen/Capsigen Deal

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Abingworth & Alebund’s Finacial Closing; Pfizer/BioNTech COVID-19 Vaccine Expanded Use; Biogen and Capsigen Deal

Abingworth Achieves Financial Close, Raises USD 582 Million Abingworth, a London-based venture capital firm, has announced the closing of its new Clinical Co-Development Fund 2 (ACCD 2) worth USD 582 million, however, the fund was aiming to gather USD $350 million. Not long ago, the company also closed on the Abingworth Bioventures 8 (ABV 8) fund at $465 million. At the moment, the company’s total fund stands over USD 1 Billion, which it plans to invest in the life science companies in the U.S, UK, and Continental Europe. Earlier, Abingworth used to invest through its co-development portfolio companies Avillion and SFJ Pharmaceuticals, which helped in t...

Explore More...

Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug

Hot flashes

Notizia

COMMERCIAL AND OTHERS

KEY CLINICAL OUTCOMES

FDA

Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray

Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand

Notizia

Johnson & Johnson

Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner

Johnson & Johnson

Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune

transthyretin amyloidosis

Notizia

Johnson & Johnson

Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research

transthyretin amyloidosis

Notizia

Johnson & Johnson

Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M

transthyretin amyloidosis

Notizia

Johnson & Johnson

4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker

FDA

Notizia

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly